Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,90
KB-0,76
PKN8282,6-2,59
Msft0,73
Nokia5,145,18-1,64
IBM-0,63
DCX61,861,82-0,95
PFE-0,55
19.6.2018 1:38:59
Indexy online
AD Index online
select
AD Index online
 

  • 18.6.2018 22:00:00
Egalet (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
0,4556 -3,72 -0,02 362 485
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.6.2018
Popis společnosti
Obecné informace
Název společnostiEgalet Corp
TickerEGLT
Kmenové akcie:Ordinary Shares
RICEGLT.O
ISINUS28226B1044
Prioritní akcieConv. Pref. Shrs Series A-1
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs Series B
Prioritní akcieConv. Pref. Shrs Series B-1
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 131
Akcie v oběhu k 11.5.2018 52 987 321
Počet akcionářů k 31.12.2017 8
MěnaUSD
Kontaktní informace
Ulice600 Lee Rd Ste 100
MěstoWAYNE
PSČ19087-5624
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 108 334 200
Fax13026555049

Business Summary: Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
Financial Summary: BRIEF: For the three months ended 31 March 2018, Egalet Corp revenues increased 15% to $6.3M. Net loss decreased 51% to $12.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain/Loss on Derivatives - Hedging increase from $12K to $5.1M (income), Interest (income) expense decrease of 22% to $3.6M (expense), Other gain decrease from $181K (expense) to $0K.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 19.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardTimothy Walbert5115.6.201515.6.2015
President, Chief Executive Officer, DirectorRobert Radie52
Chief Financial Officer, Executive Vice President, SecretaryStanley Musial55
Chief Operating Officer, Executive Vice PresidentMark Strobeck45
Senior Vice President, General CounselPaul Varki-16.11.201516.11.2015
Senior Vice President - CommunicationsE. Blair Clark-Schoeb-
Senior Vice President - Research & DevelopmentKarsten Lindhardt44
Chief Accounting OfficerBarbara Carlin411.1.20161.1.2016
Chief Medical OfficerJeffrey Dayno6031.7.201431.7.2014
Chief Commercial OfficerPatrick Shea-19.9.201619.9.2016